Cullinan Therapeutics Inc’s recently made public that its Chief Scientific Officer Michaelson Jennifer unloaded Company’s shares for reported $49200.0 on Nov 24 ’25. In the deal valued at $12.30 per share,4,000 shares were sold. As a result of this transaction, Michaelson Jennifer now holds 138,004 shares worth roughly $1.57 million.
Then, JENNIFER MICHAELSON bought 4,000 shares, generating $37,880 in total proceeds.
Before that, Lynx1 Capital Management LP bought 165,667 shares. Cullinan Therapeutics Inc shares valued at $1,391,686 were divested by the 10% Owner at a price of $8.40 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 8,963,500 shares, worth roughly $101.91 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Friday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -3.15% to $11.37. Over the last five days, the stock has gained 30.39%. Cullinan Therapeutics Inc shares have fallen nearly -9.33% since the year began. Nevertheless, the stocks have fallen -6.65% over the past one year. While a 52-week high of $13.78 was reached on 11/24/25, a 52-week low of $5.68 was recorded on 10/03/25.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 11.08, which if violated will result in even more drops to 10.78. On the upside, there is a resistance level at 11.84. A further resistance level may holdings at 12.30.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-11-14, growing by 49049.0 shares to a total of 6.68 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 6.63 million shares. There was a rise of 0.73%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
